Rigel Pharmaceuticals (RIGL) Stock Forecast, Price Target & Predictions
RIGL Stock Forecast
Rigel Pharmaceuticals stock forecast is as follows: an average price target of $1.50 (represents a -91.22% downside from RIGL’s last price of $17.09) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
RIGL Price Target
The average price target for Rigel Pharmaceuticals (RIGL) is $1.50 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $2.00 to $1.00. This represents a potential -91.22% downside from RIGL's last price of $17.09.
RIGL Analyst Ratings
According to 5 Wall Street analysts, Rigel Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for RIGL stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Rigel Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 17, 2022 | Piper Sandler | $2.00 | $1.56 | 28.21% | -88.30% | |
| Jun 08, 2022 | Eun Yang | Jefferies | $1.00 | $0.71 | 41.04% | -94.15% |
The latest Rigel Pharmaceuticals stock forecast, released on Aug 17, 2022 by Piper Sandler company, set a price target of $2.00, which represents a 28.21% increase from the stock price at the time of the forecast ($1.56), and a -88.30% decrease from RIGL last price ($17.09).
Rigel Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $17.09 | $17.09 | $17.09 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Rigel Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Rigel Pharmaceuticals's last price of $17.09. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 11, 2024 | Citigroup | Buy | Buy | Hold |
| Sep 03, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 07, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Dec 02, 2022 | Citigroup | Buy | Upgrade | |
| Aug 18, 2022 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 16, 2022 | Piper Sandler | Neutral | Neutral | Hold |
| Jun 09, 2022 | BMO Capital | Outperform | Outperform | Hold |
| Jun 08, 2022 | Jefferies | Buy | Downgrade | |
| Jun 08, 2022 | H.C. Wainwright | Buy | Buy | Hold |
Rigel Pharmaceuticals's last stock rating was published by Citigroup on Nov 11, 2024. The company gave RIGL a "Buy" rating, the same as its previous rate.
Rigel Pharmaceuticals Financial Forecast
Rigel Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $28.13M | $26.89M | $26.07M | $51.28M | $22.41M | $29.82M | $16.73M | $20.41M | $21.54M | $26.27M | $81.02M | $18.45M | $18.39M | $16.02M | $55.76M | $15.40M | $20.86M | $10.41M | $12.62M | $3.58M | $5.03M |
| Avg Forecast | $50.83M | $49.61M | $47.09M | $43.49M | $47.43M | $41.94M | $33.42M | $31.47M | $34.10M | $27.20M | $25.70M | $24.07M | $36.52M | $22.61M | $23.65M | $17.58M | $21.90M | $23.56M | $20.37M | $30.85M | $18.37M | $17.24M | $13.75M | $56.71M | $15.66M | $11.96M | $9.28M | $11.72M | $3.30M | $5.03M |
| High Forecast | $52.27M | $51.03M | $48.43M | $44.73M | $49.47M | $41.94M | $33.42M | $31.47M | $35.07M | $27.20M | $26.44M | $24.76M | $37.56M | $22.61M | $23.65M | $17.58M | $21.90M | $23.56M | $20.37M | $30.85M | $18.37M | $17.24M | $13.75M | $56.71M | $15.66M | $11.96M | $9.28M | $11.72M | $3.97M | $6.04M |
| Low Forecast | $49.19M | $48.02M | $45.57M | $42.09M | $44.67M | $41.94M | $33.42M | $31.47M | $33.00M | $27.20M | $24.88M | $23.30M | $35.35M | $22.61M | $23.65M | $17.58M | $21.90M | $23.56M | $20.37M | $30.85M | $18.37M | $17.24M | $13.75M | $56.71M | $15.66M | $11.96M | $9.28M | $11.72M | $2.64M | $4.02M |
| # Analysts | 1 | 1 | 1 | 1 | 5 | 4 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 16 | 8 | 10 | 16 | 18 | 12 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.03% | 1.05% | 1.08% | 1.40% | 0.99% | 1.26% | 0.95% | 0.93% | 0.91% | 1.29% | 2.63% | 1.00% | 1.07% | 1.17% | 0.98% | 0.98% | 1.74% | 1.12% | 1.08% | 1.08% | 1.00% |
Rigel Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 3 analysts is $34.10M, with a low forecast of $33.00M, and a high forecast of $35.07M. RIGL's average Quarter revenue forecast represents a 21.21% increase compared to the company's last Quarter revenue of $28.13M (Sep 23).
Rigel Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 5 | 4 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 16 | 8 | 10 | 16 | 18 | 12 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-4.46M | $-5.27M | $-11.97M | $3.83M | $-17.97M | $-12.69M | $-26.00M | $-21.00M | $-19.51M | $-12.77M | $41.99M | $-18.60M | $-13.58M | $-17.06M | $21.56M | $-16.69M | $-11.32M | $-20.43M | $-17.43M | $-15.19M | $-17.14M |
| Avg Forecast | $-19.56M | $-19.09M | $-18.12M | $-16.73M | $-18.25M | $-16.13M | $-12.86M | $-26.97M | $-13.12M | $-10.47M | $-9.89M | $-24.52M | $-15.84M | $-8.64M | $-9.04M | $-22.29M | $-8.37M | $-9.01M | $-7.79M | $-11.80M | $-7.03M | $-6.59M | $-5.26M | $21.56M | $-5.99M | $-4.57M | $-3.55M | $-20.12M | $-13.92M | $-17.14M |
| High Forecast | $-18.93M | $-18.47M | $-17.54M | $-16.19M | $-17.19M | $-16.13M | $-12.86M | $-21.58M | $-12.70M | $-10.46M | $-9.57M | $-19.61M | $-12.67M | $-8.64M | $-9.04M | $-17.83M | $-8.37M | $-9.01M | $-7.79M | $-11.80M | $-7.03M | $-6.59M | $-5.26M | $25.87M | $-5.99M | $-4.57M | $-3.55M | $-16.09M | $-11.14M | $-13.71M |
| Low Forecast | $-20.11M | $-19.63M | $-18.64M | $-17.21M | $-19.03M | $-16.14M | $-12.86M | $-32.36M | $-13.49M | $-10.47M | $-10.17M | $-29.42M | $-19.00M | $-8.64M | $-9.04M | $-26.75M | $-8.37M | $-9.01M | $-7.79M | $-11.80M | $-7.03M | $-6.59M | $-5.26M | $17.24M | $-5.99M | $-4.57M | $-3.55M | $-24.14M | $-16.71M | $-20.57M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.43% | 0.53% | 0.49% | -0.24% | 2.08% | 1.40% | 1.17% | 2.51% | 2.17% | 1.64% | -3.56% | 2.65% | 2.06% | 3.25% | 1.00% | 2.79% | 2.47% | 5.76% | 0.87% | 1.09% | 1.00% |
1 analysts predict RIGL's average Quarter EBITDA for Mar 23 to be $-24.52M, with a high of $-19.61M and a low of $-29.42M. This is -740.47% lower than Rigel Pharmaceuticals's previous annual EBITDA (Dec 22) of $3.83M.
Rigel Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 5 | 4 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 16 | 8 | 10 | 16 | 18 | 12 |
| Net Income | - | - | - | - | - | - | - | - | - | $-5.69M | $-6.60M | $-14.35M | $723.00K | $-19.67M | $-14.02M | $-28.63M | $-22.64M | $-20.95M | $-13.82M | $39.50M | $-19.24M | $-14.17M | $-17.58M | $21.24M | $-17.20M | $-11.49M | $-20.61M | $-17.60M | $-15.31M | $-17.46M |
| Avg Forecast | $2.82M | $3.53M | $4.68M | $3.00M | $5.28M | $1.03M | $-5.15M | $-28.46M | $-3.60M | $-12.53M | $-13.77M | $-25.88M | $-16.32M | $-23.20M | $-21.53M | $-23.52M | $-22.25M | $-17.49M | $-19.19M | $711.00M | $-19.65M | $-21.36M | $-23.42M | $21.24M | $-14.24M | $-19.32M | $-24.12M | $-20.31M | $-14.04M | $-17.46M |
| High Forecast | $2.93M | $3.66M | $4.85M | $3.11M | $10.05M | $1.04M | $-4.94M | $-22.77M | $-1.20M | $-12.00M | $-13.19M | $-20.70M | $-13.05M | $-23.20M | $-21.53M | $-18.82M | $-22.25M | $-17.49M | $-19.19M | $853.20M | $-19.65M | $-21.36M | $-23.42M | $25.49M | $-14.24M | $-19.32M | $-24.12M | $-16.24M | $-11.23M | $-13.97M |
| Low Forecast | $2.71M | $3.38M | $4.48M | $2.87M | $2.21M | $1.03M | $-5.35M | $-34.16M | $-5.99M | $-12.99M | $-14.28M | $-31.05M | $-19.58M | $-23.20M | $-21.53M | $-28.23M | $-22.25M | $-17.49M | $-19.19M | $568.80M | $-19.65M | $-21.36M | $-23.42M | $16.99M | $-14.24M | $-19.32M | $-24.12M | $-24.37M | $-16.85M | $-20.96M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.45% | 0.48% | 0.55% | -0.04% | 0.85% | 0.65% | 1.22% | 1.02% | 1.20% | 0.72% | 0.06% | 0.98% | 0.66% | 0.75% | 1.00% | 1.21% | 0.59% | 0.85% | 0.87% | 1.09% | 1.00% |
Rigel Pharmaceuticals's average Quarter net income forecast for Mar 23 is $-25.88M, with a range of $-31.05M to $-20.70M. RIGL's average Quarter net income forecast represents a -3679.08% decrease compared to the company's last Quarter net income of $723.00K (Dec 22).
Rigel Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 5 | 4 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 16 | 8 | 10 | 16 | 18 | 12 |
| SG&A | - | - | - | - | - | - | - | - | - | $24.86M | $26.31M | $27.73M | $32.17M | $25.90M | $26.98M | $27.40M | $24.52M | $22.88M | $22.38M | $22.12M | $21.82M | $17.43M | $18.92M | $18.43M | $18.31M | $18.12M | $18.21M | $19.95M | $7.41M | $4.42M |
| Avg Forecast | $44.92M | $43.85M | $41.62M | $38.44M | $41.91M | $37.06M | $29.53M | $28.42M | $30.14M | $24.04M | $22.72M | $21.27M | $17.37M | $19.98M | $20.91M | $15.53M | $19.35M | $20.82M | $18.00M | $27.27M | $16.24M | $15.23M | $12.15M | $18.43M | $13.84M | $10.57M | $8.20M | $10.36M | $2.92M | $4.42M |
| High Forecast | $46.20M | $45.10M | $42.80M | $39.53M | $43.72M | $37.06M | $29.54M | $34.10M | $31.00M | $24.04M | $23.36M | $21.88M | $20.85M | $19.98M | $20.91M | $15.53M | $19.35M | $20.82M | $18.00M | $27.27M | $16.24M | $15.23M | $12.15M | $22.12M | $13.84M | $10.57M | $8.20M | $10.36M | $3.50M | $5.31M |
| Low Forecast | $43.47M | $42.43M | $40.28M | $37.20M | $39.48M | $37.06M | $29.53M | $22.73M | $29.17M | $24.04M | $21.98M | $20.59M | $13.90M | $19.98M | $20.91M | $15.53M | $19.35M | $20.82M | $18.00M | $27.27M | $16.24M | $15.23M | $12.15M | $14.74M | $13.84M | $10.57M | $8.20M | $10.36M | $2.34M | $3.54M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.03% | 1.16% | 1.30% | 1.85% | 1.30% | 1.29% | 1.76% | 1.27% | 1.10% | 1.24% | 0.81% | 1.34% | 1.14% | 1.56% | 1.00% | 1.32% | 1.71% | 2.22% | 1.93% | 2.54% | 1.00% |
Rigel Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $30.14M, based on 3 Wall Street analysts, with a range of $29.17M to $31.00M. The forecast indicates a 21.25% rise compared to RIGL last annual SG&A of $24.86M (Sep 23).
Rigel Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 5 | 4 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 16 | 8 | 10 | 16 | 18 | 12 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.03 | $-0.04 | $-0.08 | - | $-0.11 | $-0.08 | $-0.17 | $-0.13 | $-0.12 | $-0.08 | $0.23 | $-0.11 | $-0.08 | $-0.10 | $0.13 | $-0.10 | $-0.07 | $-0.12 | $-0.11 | $-0.13 | $-0.19 |
| Avg Forecast | $0.16 | $0.20 | $0.27 | $0.17 | $0.30 | $0.06 | $-0.29 | $-0.29 | $-0.20 | $-0.71 | $-0.78 | $-0.96 | $-0.95 | $-1.32 | $-1.23 | $-1.37 | $-1.27 | $-1.00 | $-1.09 | $0.05 | $-1.12 | $-1.22 | $-1.33 | $1.32 | $-0.81 | $-1.10 | $-1.37 | $-1.28 | $-0.11 | $-0.19 |
| High Forecast | $0.17 | $0.21 | $0.27 | $0.18 | $0.57 | $0.06 | $-0.28 | $-0.28 | $-0.07 | $-0.68 | $-0.75 | $-0.92 | $-0.91 | $-1.32 | $-1.23 | $-1.37 | $-1.27 | $-1.00 | $-1.09 | $0.05 | $-1.12 | $-1.22 | $-1.33 | $1.32 | $-0.81 | $-1.10 | $-1.37 | $-1.28 | $-0.09 | $-0.15 |
| Low Forecast | $0.15 | $0.19 | $0.25 | $0.16 | $0.13 | $0.06 | $-0.30 | $-0.30 | $-0.34 | $-0.74 | $-0.81 | $-0.99 | $-0.98 | $-1.32 | $-1.23 | $-1.37 | $-1.27 | $-1.00 | $-1.09 | $0.05 | $-1.12 | $-1.22 | $-1.33 | $1.32 | $-0.81 | $-1.10 | $-1.37 | $-1.28 | $-0.13 | $-0.23 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.05% | 0.05% | 0.09% | -0.00% | 0.08% | 0.07% | 0.12% | 0.10% | 0.12% | 0.07% | 4.71% | 0.10% | 0.07% | 0.07% | 0.10% | 0.12% | 0.06% | 0.09% | 0.09% | 1.18% | 1.00% |
According to 1 Wall Street analysts, Rigel Pharmaceuticals's projected average Quarter EPS for Mar 23 is $-0.96, with a low estimate of $-0.99 and a high estimate of $-0.92. This represents a -22905.71% decrease compared to RIGL previous annual EPS of - (Dec 22).
Rigel Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ELEV | Elevation Oncology | $0.67 | $9.00 | 1243.28% | Buy |
| RVPH | Reviva Pharmaceuticals | $1.40 | $10.00 | 614.29% | Buy |
| INZY | Inozyme Pharma | $2.94 | $16.00 | 444.22% | Buy |
| XFOR | X4 Pharmaceuticals | $0.74 | $3.67 | 395.95% | Buy |
| ZURA | Zura Bio | $2.51 | $10.00 | 298.41% | Buy |
| ABOS | Acumen Pharmaceuticals | $1.96 | $7.00 | 257.14% | Buy |
| IMMX | Immix Biopharma | $2.29 | $7.00 | 205.68% | Buy |
| TERN | Terns Pharmaceuticals | $6.80 | $18.67 | 174.56% | Buy |
| MREO | Mereo BioPharma Group | $3.40 | $8.00 | 135.29% | Buy |
| DAWN | Day One Biopharmaceuticals | $12.64 | $24.00 | 89.87% | Buy |
| LPTX | Leap Therapeutics | $3.11 | $5.50 | 76.85% | Buy |
| CDTX | Cidara Therapeutics | $22.81 | $12.00 | -47.39% | Buy |
| RIGL | Rigel Pharmaceuticals | $18.45 | $1.50 | -91.87% | Buy |